Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19059303 | METHOD FOR IDENTIFYING A SHARED NEOANTIGEN-REACTIVE T CELL RECEPTOR | February 2025 | August 2025 | Allow | 6 | 1 | 0 | No | No |
| 18991315 | Subcutaneous anti-HER2 Antibody Formulations and Uses Thereof | December 2024 | March 2025 | Allow | 3 | 1 | 0 | No | No |
| 18635280 | Subcutaneous anti-HER2 Antibody Formulations and Uses Thereof | April 2024 | January 2026 | Abandon | 21 | 1 | 0 | No | No |
| 18628200 | RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS | April 2024 | February 2025 | Allow | 11 | 1 | 0 | No | No |
| 18619805 | ANTI-OX40 ANTAGONISTIC ANTIBODIES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | March 2024 | October 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18592208 | METHODS OF TREATING TUMOR | February 2024 | March 2025 | Allow | 12 | 1 | 0 | No | No |
| 18417162 | PROSTATE ANTIGEN STANDARDS AND USES THEREOF | January 2024 | August 2025 | Allow | 19 | 2 | 1 | No | No |
| 18408377 | METHODS OF USING ANTI-SP17 IMMUNOTHERAPEUTICS | January 2024 | November 2024 | Allow | 10 | 1 | 0 | Yes | No |
| 18396461 | ANTI-TSPAN8/ANTI-CD3 BISPECIFIC ANTIBODY AND ANTI-TSPAN8 ANTIBODY | December 2023 | January 2025 | Allow | 13 | 1 | 0 | No | No |
| 18542441 | T CELL RECEPTORS AND FUSION PROTEINS THEREOF | December 2023 | April 2024 | Allow | 4 | 0 | 0 | No | No |
| 18537973 | COMPOSITION OF BL-8040 | December 2023 | October 2024 | Allow | 10 | 2 | 0 | Yes | No |
| 18532450 | SYSTEMS AND METHODS FOR BARRETT'S ESOPHAGUS PATHOGENESIS AND ESOPHAGEAL ADENOCARCINOMA PROGRESSION REVEALING MARKERS | December 2023 | March 2025 | Allow | 16 | 2 | 1 | No | No |
| 18531287 | DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES | December 2023 | August 2024 | Abandon | 8 | 0 | 0 | No | No |
| 18529758 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | December 2023 | February 2025 | Allow | 14 | 2 | 0 | No | No |
| 18529140 | COMBINATION CANCER THERAPY | December 2023 | December 2025 | Abandon | 24 | 2 | 0 | Yes | Yes |
| 18516168 | RESPONSE TO EGFR BLOCKADE | November 2023 | April 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18495585 | CIRCULATING TUMOR CELL DIAGNOSTICS FOR BIOMARKERS PREDICTIVE OF RESISTANCE TO ANDROGEN RECEPTOR (AR) TARGETED THERAPIES | October 2023 | September 2025 | Abandon | 22 | 1 | 0 | No | Yes |
| 18487818 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING PROSTATE CANCER BASED ON LONG NONCODING RNA OVERLAPPING THE LCK GENE THAT REGULATES PROSTATE CANCER CELL GROWTH | October 2023 | April 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18475552 | Anti-TIM-3 Antibodies and Use Thereof | September 2023 | February 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18471388 | HUMANIZED ANTI-IL-1R3 ANTIBODY AND METHODS OF USE | September 2023 | March 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18469913 | METHODS AND SYSTEMS FOR SELECTIVE QUANTITATION AND DETECTION OF ALLERGENS INCLUDING GLY M 7 | September 2023 | January 2026 | Abandon | 27 | 1 | 0 | No | No |
| 18463209 | HETERODIMERIC PROTEINS | September 2023 | May 2025 | Allow | 20 | 1 | 0 | No | No |
| 18462648 | OVARIAN CANCER VACCINES | September 2023 | March 2025 | Allow | 18 | 2 | 0 | No | No |
| 18459857 | Subcutaneous anti-HER2 Antibody Formulations and Uses Thereof | September 2023 | June 2024 | Abandon | 10 | 1 | 0 | No | No |
| 18456044 | NOVEL THI-INDUCING ADJUVANT COMPRISING COMBINATION OF DIFFERENT NUCLEIC ACID ADJUVANTS AND USE OF SAME | August 2023 | May 2025 | Allow | 21 | 3 | 0 | No | No |
| 18455176 | IMMUNE-STIMULATING IL-2 FUSION PROTEINS | August 2023 | October 2025 | Abandon | 25 | 0 | 1 | No | No |
| 18263430 | ANTI-NECTIN-4-ANTIBODIES AND USES THEREOF | July 2023 | March 2024 | Allow | 8 | 1 | 0 | No | No |
| 18270521 | COMPOSITION OF BL-8040 | June 2023 | January 2025 | Allow | 19 | 1 | 0 | No | No |
| 18340774 | NEUROPILIN-1-PEPTIDE BASED ANTIBODY, HIGHLIGHTING NEW EPITOPE ASSOCIATED TO GLYCOSAMINOGLYCAN-MODIFIED NEUROPILIN-1 AND METHODS OF USE THEREOF | June 2023 | December 2023 | Allow | 5 | 0 | 0 | No | No |
| 18213132 | HUMANIZED CC CHEMOKINE RECEPTOR 4 (CCR4) ANTIBODIES AND METHODS OF USE THEREOF | June 2023 | February 2025 | Allow | 20 | 2 | 0 | No | No |
| 18211038 | Methods of Assaying Neoplastic and Neoplasia-Related Cells and Uses Thereof | June 2023 | January 2025 | Allow | 19 | 2 | 0 | No | No |
| 18325497 | BIOMARKERS FOR CANCER IMMUNOTHERAPY OUTCOMES | May 2023 | January 2025 | Abandon | 19 | 0 | 1 | No | No |
| 18200000 | ANTITUMOR PHARMACEUTICAL COMPOSITION COMPRISING AZVUDINE AND CHEMOTHERAPEUTIC AGENT | May 2023 | January 2025 | Allow | 20 | 6 | 0 | No | No |
| 18036610 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING PROSTATE CANCER BASED ON LONG NONCODING RNA OVERLAPPING THE LCK GENE THAT REGULATES PROSTATE CANCER CELL GROWTH | May 2023 | May 2025 | Abandon | 25 | 2 | 0 | Yes | No |
| 18308579 | DETECTION OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) EXPRESSION ON CIRCULATING TUMOR CELLS (CTC) | April 2023 | September 2025 | Abandon | 29 | 2 | 0 | No | Yes |
| 18308623 | HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS | April 2023 | March 2025 | Allow | 22 | 1 | 1 | No | No |
| 18134293 | METHODS OF TREATING COLON CANCER USING NANOPARTICLE MTOR INHIBITOR COMBINATION THERAPY | April 2023 | December 2024 | Abandon | 20 | 1 | 0 | No | No |
| 18133822 | TREATMENT OF CANCER WITH ANTI-GITR AGONIST ANTIBODIES | April 2023 | September 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18298807 | THERAPEUTIC TREATMENT OF BREAST CANCER BASED ON C-MAF STATUS | April 2023 | October 2024 | Allow | 18 | 1 | 0 | No | No |
| 18126275 | SYNTHETIC LETHALITY AND THE TREATMENT OF CANCER | March 2023 | March 2025 | Abandon | 24 | 1 | 1 | No | No |
| 18186762 | Immunotherapy Methods for Patients Whose Tumors Carry a High Passenger Gene Mutation Burden | March 2023 | October 2024 | Allow | 19 | 1 | 0 | No | No |
| 18185736 | IMMUNOMODULATORY ANTIBODIES AND METHODS OF USE THEREOF | March 2023 | August 2024 | Allow | 17 | 1 | 0 | No | No |
| 18182297 | NOVEL HETERODIMERIC PROTEINS | March 2023 | January 2026 | Abandon | 34 | 2 | 1 | No | Yes |
| 18025640 | APPLICATION OF BACTERIA IN PREPARATION OF SYNERGIST FOR IMMUNE CHECKPOINT INHIBITOR | March 2023 | February 2026 | Allow | 35 | 1 | 0 | No | No |
| 18175420 | ANTIBODIES AGAINST TIM3 AND USES THEREOF | February 2023 | January 2025 | Allow | 23 | 2 | 0 | No | No |
| 18173417 | DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES | February 2023 | January 2024 | Abandon | 11 | 0 | 0 | No | No |
| 18171569 | METHODS OF DETECTING PROSTATE CANCER | February 2023 | August 2024 | Allow | 18 | 1 | 1 | Yes | No |
| 18164417 | CHIMERIC ILT RECEPTOR COMPOSITIONS AND METHODS | February 2023 | February 2025 | Allow | 24 | 3 | 0 | Yes | No |
| 18163723 | BIOMARKERS FOR PREDICTING TUMOR RESPONSE TO AND TOXICITY OF IMMUNOTHERAPY | February 2023 | January 2025 | Allow | 23 | 1 | 0 | No | No |
| 18157717 | PREDICTIVE AND DIAGNOSTIC METHODS FOR PROSTATE CANCER | January 2023 | August 2024 | Abandon | 19 | 1 | 0 | No | No |
| 18151297 | APTAMER BASED AFFINITY CAPTURE METHODS FOR THE SELECTIVE ENRICHMENT OF HUMAN IMMUNOGLOBULIN FC DOMAINS | January 2023 | April 2025 | Abandon | 27 | 2 | 0 | No | No |
| 18149881 | MIR-3132 UPREGULATION OF THE TRAIL PATHWAY AND APOPTOTIC ACTIVITY IN CANCER CELLS | January 2023 | April 2024 | Allow | 15 | 1 | 0 | Yes | No |
| 18088184 | TUMOR MICROENVIRONMENT-BASED METHODS FOR ASSESSING CAR-T AND OTHER IMMUNOTHERAPIES | December 2022 | November 2025 | Allow | 35 | 5 | 0 | No | No |
| 18082368 | NANOPARTICLES AND DISTINCT EXOSOME SUBSETS FOR DETECTION AND TREATMENT OF CANCER | December 2022 | November 2024 | Allow | 23 | 2 | 1 | No | No |
| 18078088 | WEEKLY DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATES | December 2022 | December 2024 | Abandon | 24 | 1 | 0 | No | No |
| 18062419 | DETECTING NEOPLASM | December 2022 | March 2024 | Allow | 15 | 1 | 0 | No | No |
| 18007859 | HIV-1 ANTIBODIES | December 2022 | November 2025 | Allow | 35 | 1 | 0 | Yes | No |
| 18057627 | Novel Method For Producing Low Viscous And Highly Concentrated Biopharmaceutical Drug Products In Liquid Formulation | November 2022 | March 2025 | Abandon | 27 | 2 | 0 | No | No |
| 17998795 | SMC1A ANTIBODIES AND USES THEREOF | November 2022 | January 2026 | Allow | 38 | 1 | 0 | No | No |
| 18054597 | ONCOLYTIC VIRUS VACCINE AND DRUG FOR TREATING TUMORS BY COMBINING ONCOLYTIC VIRUS VACCINE WITH IMMUNE CELLS | November 2022 | October 2025 | Allow | 35 | 1 | 0 | No | No |
| 18054307 | METHODS FOR THE DETECTION AND TREATMENT OF PANCREATIC DUCTAL ADENOCARCINOMA | November 2022 | June 2025 | Abandon | 31 | 4 | 0 | No | No |
| 17924542 | COMPOSITION FOR THE TREATMENT AND/OR PREVENTION OF MARINE MOLLUSC VIRAL INFECTION | November 2022 | January 2026 | Abandon | 39 | 1 | 0 | No | No |
| 18047285 | VIRUS COMPOSITION | October 2022 | August 2024 | Allow | 22 | 1 | 1 | No | No |
| 17968386 | N6-Methyladenosine Regulators in Uterine Fibroids | October 2022 | March 2026 | Allow | 41 | 2 | 1 | No | No |
| 18047216 | METHODS OF TREATING TUMOR | October 2022 | October 2023 | Allow | 12 | 1 | 0 | Yes | No |
| 18046565 | NON-INVASIVE TEST TO PREDICT RESPONSE TO THERAPY IN COLORECTAL CANCER PATIENTS | October 2022 | October 2024 | Abandon | 24 | 2 | 0 | No | No |
| 17932259 | CHIMERIC ANTIGEN RECEPTOR AND METHODS OF USE THEREOF | September 2022 | August 2024 | Allow | 23 | 2 | 0 | No | No |
| 17940883 | PLASMA AUTOANTIBODY BIOMARKERS FOR BASAL LIKE BREAST CANCER | September 2022 | May 2024 | Allow | 20 | 1 | 2 | No | No |
| 17904098 | USE OF ANTI-PD-1 ANTIBODY IN TREATING NEUROENDOCRINE TUMORS | August 2022 | January 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17760202 | METHODS FOR DISCONTINUING A TREATMENT WITH A TYROSINE KINASE INHIBITOR (TKI) | August 2022 | January 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17817886 | IMMUNE-STIMULATING IL-2 FUSION PROTEINS | August 2022 | May 2023 | Allow | 10 | 2 | 0 | Yes | No |
| 17817862 | DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES | August 2022 | May 2023 | Abandon | 9 | 0 | 0 | No | No |
| 17797662 | ZIKA VIRUS IMMUNOGENIC COMPOSITIONS | August 2022 | September 2025 | Allow | 37 | 1 | 0 | No | No |
| 17796788 | FUSION ANTIBODY FOR PRESENTING ANTIGEN-DERIVED T CELL ANTIGEN EPITOPE OR PEPTIDE CONTAINING SAME ON CELL SURFACE, AND COMPOSITION COMPRISING SAME | August 2022 | October 2025 | Allow | 39 | 2 | 0 | No | No |
| 17793503 | RECOMBINANT FULLY HUMAN ANTI-TIGIT MONOCLONAL ANTIBODY FORMULATION, METHOD FOR PREPARING SAME AND USE THEREOF | July 2022 | January 2026 | Abandon | 42 | 1 | 0 | No | No |
| 17792250 | METHODS FOR THE TREATMENT OF CANCER | July 2022 | December 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17789888 | USE OF THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF PATIENTS WITH TUMORS OF EPITHELIAL ORIGIN | June 2022 | March 2026 | Allow | 45 | 4 | 0 | No | No |
| 17848694 | RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS | June 2022 | November 2023 | Allow | 17 | 1 | 0 | Yes | No |
| 17846966 | BIOMARKERS AND USES THEREOF FOR SELECTING IMMUNOTHERAPY INTERVENTION | June 2022 | April 2024 | Abandon | 21 | 1 | 1 | Yes | No |
| 17843852 | METHODS OF TREATING FIBROBLAST GROWTH FACTOR 19-MEDIATED CANCERS AND TUMORS | June 2022 | June 2025 | Abandon | 36 | 1 | 0 | No | No |
| 17785484 | METHOD FOR PREDICTING SENSITIVITY OF CANCER CELL TO GPX4 INHIBITOR | June 2022 | September 2025 | Allow | 39 | 1 | 0 | No | No |
| 17806218 | CD3/CD38 T CELL RETARGETING HETERO-DIMERIC IMMUNOGLOBULINS AND METHODS OF THEIR PRODUCTION | June 2022 | February 2024 | Allow | 20 | 2 | 0 | No | No |
| 17783439 | METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING A SAGE1-RELATED CONDITION | June 2022 | November 2025 | Allow | 42 | 2 | 1 | No | No |
| 17805336 | CANCER TREATMENT | June 2022 | July 2024 | Abandon | 25 | 2 | 0 | No | No |
| 17826477 | BIOMARKERS PREDICTIVE OF ANTI-IMMUNE CHECKPOINT RESPONSE | May 2022 | April 2025 | Allow | 35 | 3 | 1 | No | No |
| 17752519 | WEEKLY DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATES | May 2022 | September 2022 | Allow | 3 | 1 | 0 | No | No |
| 17778446 | INHIBITORS OF ADRENOMEDULLIN FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA BY ERADICATING LEUKEMIC STEM CELLS | May 2022 | December 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17744262 | METHODS FOR TREATMENT OF CD20-POSITIVE PROLIFERATIVE DISORDER WITH MOSUNETUZUMAB AND POLATUZUMAB VEDOTIN | May 2022 | February 2025 | Allow | 33 | 4 | 0 | No | No |
| 17739308 | HUMANIZED, MOUSE OR CHIMERIC ANTI-CD47 MONOCLONAL ANTIBODIES | May 2022 | April 2024 | Allow | 24 | 1 | 0 | Yes | No |
| 17739317 | TCR, POLYPEPTIDE, EXPRESSION VECTOR, HOST CELL, PHARMACEUTICAL COMPOSITION AND METHOD FOR OBTAINING TCR | May 2022 | November 2024 | Allow | 31 | 3 | 1 | No | No |
| 17736475 | HETERODIMERIC ANTIBODIES THAT BIND CD3 AND CD38 | May 2022 | June 2024 | Allow | 25 | 1 | 1 | No | No |
| 17722051 | NON-CODING RNA FOR DETECTION OF CANCER | April 2022 | November 2023 | Abandon | 19 | 3 | 0 | Yes | No |
| 17769245 | METHODS FOR DETECTING AND INHIBITING BRAIN METASTASIS | April 2022 | December 2025 | Allow | 44 | 2 | 0 | Yes | No |
| 17715092 | DETECTION OF DESMOGLEIN-2 IN CANCERS OF EPITHELIAL ORIGIN | April 2022 | March 2026 | Allow | 47 | 2 | 0 | No | No |
| 17762703 | BIOMARKER PANEL TARGETED TO DISEASES DUE TO MULTIFACTORIAL ONTOLOGY OF GLYCOCALYX DISRUPTION | March 2022 | January 2026 | Allow | 46 | 2 | 1 | No | No |
| 17762530 | BIOMARKERS FOR ANTI-TIGIT ANTIBODY TREATMENT | March 2022 | November 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17760869 | Methods and Kit for Analyzing Responsiveness of Patients to CD19 Immunotherapy | March 2022 | September 2025 | Allow | 42 | 2 | 0 | No | No |
| 17654801 | Method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases | March 2022 | September 2023 | Allow | 18 | 1 | 0 | No | No |
| 17690634 | METHODS FOR THE TREATMENT OF CANCER | March 2022 | June 2024 | Abandon | 27 | 2 | 0 | No | No |
| 17639783 | ANTI-TSPAN8/ANTI-CD3 BISPECIFIC ANTIBODY AND ANTI-TSPAN8 ANTIBODY | March 2022 | September 2023 | Allow | 19 | 0 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner AEDER, SEAN E.
With a 45.2% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 18.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner AEDER, SEAN E works in Art Unit 1642 and has examined 1,644 patent applications in our dataset. With an allowance rate of 51.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.
Examiner AEDER, SEAN E's allowance rate of 51.0% places them in the 13% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by AEDER, SEAN E receive 2.39 office actions before reaching final disposition. This places the examiner in the 68% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by AEDER, SEAN E is 33 months. This places the examiner in the 46% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +28.0% benefit to allowance rate for applications examined by AEDER, SEAN E. This interview benefit is in the 75% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 17.9% of applications are subsequently allowed. This success rate is in the 16% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 41.8% of cases where such amendments are filed. This entry rate is in the 64% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 58.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 49% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 73.9% of appeals filed. This is in the 63% percentile among all examiners. Of these withdrawals, 75.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 76.8% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 7.5% of allowed cases (in the 90% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.2% of allowed cases (in the 63% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.